New hope for rare skin cancer: drug after transplant may stop relapse
NCT ID NCT07178457
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 30 times
Summary
This study tests whether giving brentuximab vedotin (a targeted drug) right after a stem cell transplant can prevent early relapse in people with advanced cutaneous T-cell lymphoma (CTCL). About 84 adults with CD30-positive mycosis fungoides who have already tried at least one systemic treatment will receive either the drug or a placebo. The goal is to see if early treatment improves how long people stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA (CTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.